These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 11410503

  • 1. The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model.
    Fisher JL, Mackie PS, Howard ML, Zhou H, Choong PF.
    Clin Cancer Res; 2001 Jun; 7(6):1654-60. PubMed ID: 11410503
    [Abstract] [Full Text] [Related]

  • 2. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V, Schroeder J, Denkert C, Kristiansen G, Schnorr D, Loening SA, Jung K, Staack A.
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [Abstract] [Full Text] [Related]

  • 3. The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.
    Tsuchiya H, Katsuo S, Matsuda E, Sunayama C, Tomita K, Ueda Y, Binder BR.
    Gen Diagn Pathol; 1995 May; 141(1):41-8. PubMed ID: 8542506
    [Abstract] [Full Text] [Related]

  • 4. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
    Rabbani SA, Gladu J.
    Cancer Res; 2002 Apr 15; 62(8):2390-7. PubMed ID: 11956102
    [Abstract] [Full Text] [Related]

  • 5. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 15; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y, Mori I, Kakudo K.
    Int J Oncol; 2006 Apr 15; 28(4):807-14. PubMed ID: 16525628
    [Abstract] [Full Text] [Related]

  • 8. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
    Bhuvarahamurthy V, Schroeder J, Kristiansen G, Roigas J, Denkert C, Johannsen M, Lein M, Loening SA, Schnorr D, Jung K, Staack A.
    Oncol Rep; 2005 Sep 15; 14(3):777-82. PubMed ID: 16077991
    [Abstract] [Full Text] [Related]

  • 9. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
    Frandsen TL, Holst-Hansen C, Nielsen BS, Christensen IJ, Nyengaard JR, Carmeliet P, Brünner N.
    Cancer Res; 2001 Jan 15; 61(2):532-7. PubMed ID: 11212246
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells.
    Hagiwara H, Sato H, Shirai S, Kobayashi S, Fukumoto K, Ishida T, Seki T, Ariga T, Yano T.
    Life Sci; 2006 Apr 04; 78(19):2249-54. PubMed ID: 16289236
    [Abstract] [Full Text] [Related]

  • 13. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice.
    Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D, Woods VL.
    Cancer Res; 1993 Oct 15; 53(20):4890-5. PubMed ID: 8402677
    [Abstract] [Full Text] [Related]

  • 14. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M, Masanobu M, Takehiko K, Shoko T, Akira F, Katsushige A, Takashi H, Yoshiyuki O, Shigeru K.
    J Lab Clin Med; 2004 Aug 15; 144(2):69-77. PubMed ID: 15322501
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
    Warnecke-Eberz U, Prenzel KL, Baldus SE, Metzger R, Dienes HP, Bollschweiler E, Hoelscher AH, Schneider PM.
    Pancreas; 2008 Mar 15; 36(2):173-7. PubMed ID: 18376309
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.
    de Bock CE, Lin Z, Itoh T, Morris D, Murrell G, Wang Y.
    FEBS J; 2005 Jul 15; 272(14):3572-82. PubMed ID: 16008557
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC.
    Pancreas; 2008 Mar 15; 36(2):160-7. PubMed ID: 18376307
    [Abstract] [Full Text] [Related]

  • 20. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
    Lutz V, Reuning U, Krüger A, Luther T, von Steinburg SP, Graeff H, Schmitt M, Wilhelm OG, Magdolen V.
    Biol Chem; 2001 May 15; 382(5):789-98. PubMed ID: 11517932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.